Mucormicosis asociada a COVID-19: Revisión de la literatura
DOI:
https://doi.org/10.46296/gt.v5i10edespag.0081Palabras clave:
COVID-19, Mucormicosis, coinfección, mucorales, Virus del SARSResumen
Introducción: La pandemia por coronavirus-19, es una infección viral, que ha ido avanzado para asociarse con afecciones oportunistas. Dentro de estas destaca la mucormicosis o también conocida como “enfermedad del hongo negro”, denominada así debido a la invasión de las células endoteliales, trombosis y necrosis tisular. Objetivo: Describir los hallazgos relevantes en relación con la epidemiología, diagnóstico y tratamiento de la mucormicosis asociada a COVID-19. Metodología se basa en la investigación de tipo secundaria mediante la revisión de literatura extraída de bases de datos como: PubMed, Medline, LILACS, Cochrane, IBECS, Scopus, SciELO, sin restricción de idioma, utilizando palabras claves de los MESH. Discusión: Los tipos de mucormicosis más frecuentes en el contexto de COVID-19 fueron la rino-órbito-cerebral, y pulmonar, aunque también existen otros tipos menos habituales como cutánea, gastrointestinal, renal y diseminada. Conclusión: La asociación entre el COVID-19 y la mucormicosis, se debe a la presencia de diversos factores de riesgo como la diabetes mellitus tipo 2 mal controlada e inmunosupresión, el espectro clínico de estas entidades es inespecífico, lo que dificulta el diagnóstico temprano, ante esto es importante un manejo multimodal que evite el retraso del inicio de tratamiento antimicótico.
Palabras claves: COVID-19, Mucormicosis, coinfección, mucorales, Virus del SARS.
Abstract
Introduction: The coronavirus-19 pandemic is a viral infection, which has been advanced to be associated with opportunistic conditions. Among these stands out mucormycosis or also known as "black fungus disease", so named due to the invasion of endothelial cells, thrombosis and tissue necrosis. Objective: was to describe the relevant findings in relation to the, diagnosis and treatment of mucormycosis associated with COVID-19. Methodology is based on secondary research by reviewing literature extracted from databases such as: PubMed, Medline, LILACS, IBECS, Cochrane, Scopus, SciELO, without language restriction, using MESH keywords. Discussion: The most common types of mucormycosis in the context of COVID-19 were rhino-orbit-cerebral, and pulmonary, although there are also other less common types such as cutaneous, gastrointestinal, renal and disseminated. Conclusion: The association between COVID-19 and mucormycosis, due to the presence of various risk factors such as poorly controlled type 2 diabetes mellitus and immunosuppression, the clinical spectrum of these entities is non-specific, which makes it difficult to diagnose early, given this it is important to multimodal management that prevents delay the start of antifungal treatment.
Keywords: COVID-19, Mucormycosis, coinfection, mucomorals, SARS Virus.
Información del manuscrito:
Fecha de recepción: 01 de junio de 2022.
Fecha de aceptación: 10 de agosto de 2022.
Fecha de publicación: 11 de agosto de 2022.
Descargas
Citas
Accinelli, R. A., Zhang-Xu, C. M., Ju-Wang, J. D., Yachachin-Chávez, J. M., Cáceres-Pizarro, J. A., B., T.-B. K., . . . Paiva-Andrade, A. (2020). COVID-19: la pandemia por el nuevo virus SARS-CoV-2. Rev Peru Med Exp Salud Pública, 37(2).
Al-Tawfiq, J. A., Alhumaid, S., Alshukairi, A. N., Temsah, M. H., Barry, M., Al Mutair, A., . . . Dhama, K. (2021). COVID-19 and mucormycosis superinfection: the perfect storm. Infection, 49(5), 833-853. https://doi.org/10.1007/s15010-021-01670-1
Ambrosioni, J., Bouchuiguir-Wafa, K., & Garbino, J. (2010). Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int J Infect Dis, 14 Suppl 3, e100-103. https://doi.org/10.1016/j.ijid.2009.11.024
Arana, C., Cuevas Ramírez, R. E., Xipell, M., Casals, J., Moreno, A., Herrera, S., . . . Esforzado, N. (2021). Mucormycosis associated with COVID-19 in two kidney transplant patients. Transpl Infect Dis, 23(4), e13652. https://doi.org/10.1111/tid.13652
Aranjani, J. M., Manuel, A., Abdul Razack, H. I., & Mathew, S. T. (2021). COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India. PLoS Negl Trop Dis, 15(11), e0009921. https://doi.org/10.1371/journal.pntd.0009921
Azhar, A., Khan, W. H., Khan, P. A., Alhosaini, K., Owais, M., & Ahmad, A. (2022). Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. J Infect Public Health, 15(4), 466-479. https://doi.org/10.1016/j.jiph.2022.02.007
Bitar, D., Van Cauteren, D., Lanternier, F., Dannaoui, E., Che, D., Dromer, F., . . . Lortholary, O. (2009). Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis, 15(9), 1395-1401. https://doi.org/10.3201/eid1509.090334
Chao, C. M., Lai, C. C., & Yu, W. L. (2022). COVID-19 associated mucormycosis - An emerging threat. J Microbiol Immunol Infect, 55(2), 183-190. https://doi.org/10.1016/j.jmii.2021.12.007
Choudhary, G. R., Aggarwal, A., Jain, V., & Jena, R. (2021). COVID-19 and fatal renal mucormycosis: Contributory or coincidental? Indian J Urol, 37(3), 270-273. https://doi.org/10.4103/iju.iju_197_21
Guinea, J., Escribano, P., Vena, A., Muñoz, P., Martínez-Jiménez, M. D. C., Padilla, B., & Bouza, E. (2017). Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS One, 12(6), e0179136. https://doi.org/10.1371/journal.pone.0179136
Hassan, M. I. A., & Voigt, K. (2019). Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol, 57(Supplement_2), S245-S256. https://doi.org/10.1093/mmy/myz011
Helmy, Y. A., Fawzy, M., Elaswad, A., Sobieh, A., Kenney, S. P., & Shehata, A. A. (2020). The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. J Clin Med, 9(4). https://doi.org/10.3390/jcm9041225
Hussain, S., Baxi, H., Riad, A., Klugarová, J., Pokorná, A., Slezáková, S., . . . Klugar, M. (2021). COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. Int J Environ Res Public Health, 18(19). https://doi.org/10.3390/ijerph181910340
Hussain, S., Riad, A., Singh, A., Klugarová, J., Antony, B., Banna, H., & Klugar, M. (2021). Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis. J Fungi (Basel), 7(11). https://doi.org/10.3390/jof7110985
Iglesias-Osores, S., & Rodriguez-Perla, H. (2020). Características Microbiológicas de Mucor sp. Revista Experiencia en Medicina del Hospital Regional Lambayeque, 6(1).
Iqbal, N., Irfan, M., Jabeen, K., Kazmi, M. M., & Tariq, M. U. (2017). Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus. J Thorac Dis, 9(2), E121-E125. https://doi.org/10.21037/jtd.2017.02.31
Iñiguez-García, M. A., del Villar-Trujillo, A., Cardona-Infante, V., Carrillo-Ponce, C., & Téllez-Becerra, J. L. (2016). Diagnóstico y tratamiento de la mucormicosis pulmonar: reporte de un caso. Rev Fac Med Univ Nac Auton Mex, 59(2).
Jeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Kong, D. C. M., & Chen, S. C. (2019). The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect, 25(1), 26-34. https://doi.org/10.1016/j.cmi.2018.07.011
Kurien, A. A., Srinivasaprasad, N. D., & Valavan, K. T. (2022). Renal infarction due to COVID-19-associated renal mucormycosis. Kidney Int, 101(3), 655. https://doi.org/10.1016/j.kint.2021.07.027
Mahalaxmi, I., Jayaramayya, K., Venkatesan, D., Subramaniam, M. D., Renu, K., Vijayakumar, P., . . . Vellingiri, B. (2021). Mucormycosis: An opportunistic pathogen during COVID-19. Environ Res, 201, 111643. https://doi.org/10.1016/j.envres.2021.111643
Martín-Gómez, M. T., & Salavert-Lletí, M. (2021). Mucormicosis: perspectiva de manejo actual y de futuro. Rev Iberoam Micol, 38, 91-100.
Nagalli, S., & Kikkeri, N. S. (2021). Mucormycosis in COVID-19: A systematic review of literature. Infez Med, 29(4), 504-512. https://doi.org/10.53854/liim-2904-2
Nayak, N., Khan, E., & Panigrahi, D. (2022). COVID-19 and Mucormycosis Coinfection: How Challenging It Is. Can J Infect Dis Med Microbiol, 2022, 8617212. https://doi.org/10.1155/2022/8617212
Paraskevis, D., Kostaki, E. G., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G., & Tsiodras, S. (2020). Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol, 79, 104212. https://doi.org/10.1016/j.meegid.2020.104212
Patel, A., Agarwal, R., Rudramurthy, S. M., Shevkani, M., Xess, I., Sharma, R., . . . Network3, M. (2021). Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. Emerg Infect Dis, 27(9), 2349-2359. https://doi.org/10.3201/eid2709.210934
Prakash, H., & Chakrabarti, A. (2019). Global Epidemiology of Mucormycosis. J Fungi (Basel), 5(1). https://doi.org/10.3390/jof5010026
Ray, S. K., & Mukherjee, S. (2021). COVID-19-Associated Mucormycosis, A New Incident in Recent Time: Is An Emerging Disease in The Near Future Impending? Avicenna J Med, 11(4), 210-216. https://doi.org/10.1055/s-0041-1735383
Ren, L. L., Wang, Y. M., Wu, Z. Q., Xiang, Z. C., Guo, L., Xu, T., . . . Wang, J. W. (2020). Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl), 133(9), 1015-1024. https://doi.org/10.1097/CM9.0000000000000722
Revankar, S. (2021). Mucormicosis (cigomicosis).
Rudramurthy, S. M., Hoenigl, M., Meis, J. F., Cornely, O. A., Muthu, V., Gangneux, J. P., . . . ISHAM, E. a. (2021). ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses, 64(9), 1028-1037. https://doi.org/10.1111/myc.13335
Ruiz Camps, I., & Salavert Lletí, M. (2018). [The treatment of mucormycosis (zygomycosis) in the 21st century]. Rev Iberoam Micol, 35(4), 217-221. https://doi.org/10.1016/j.riam.2018.09.001
Salud, O. P. d. l., & Salud, O. M. d. l. (2021). Alerta Epidemiológica: Mucormicosis asociada a COVID-19. In. Washington D.C.: OPS/OMS.
Sen, M., Honavar, S. G., Bansal, R., Sengupta, S., Rao, R., Kim, U., . . . Group, m. o. t. C. O.-I. S. o. M. i. C.-C. S. (2021). Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol, 69(7), 1670-1692. https://doi.org/10.4103/ijo.IJO_1565_21
Singh, A. K., Singh, R., Joshi, S. R., & Misra, A. (2021). Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr, 15(4), 102146. https://doi.org/10.1016/j.dsx.2021.05.019
Skiada, A., Lass-Floerl, C., Klimko, N., Ibrahim, A., Roilides, E., & Petrikkos, G. (2018). Challenges in the diagnosis and treatment of mucormycosis. Med Mycol, 56(suppl_1), 93-101. https://doi.org/10.1093/mmy/myx101
Sánchez, A. J., Aparicio, K., Miranda, C. E., Castillo, C. R., & Arellano, N. B. (2021). COVID-19: epidemiología, virología y transmisibilidad. Revista Eugenio Espejo, 15(3), 89-99.
Wei, L. W., Zhu, P. Q., Chen, X. Q., & Yu, J. (2022). Mucormycosis in Mainland China: A Systematic Review of Case Reports. Mycopathologia, 187(1), 1-14. https://doi.org/10.1007/s11046-021-00607-4
Publicado
Cómo citar
Número
Sección
Derechos de autor 2022 Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. ISSN: 2737-6273.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.